| [1] |
CHAGAS AL, FELGA G, DINIZ MA, et al. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: Clinical profile and prognostic factors of survival[J]. Eur J Gastroenterol Hepatol, 2019, 31(9): 1148-1156. DOI: 10.1097/MEG.0000000000001448 |
| [2] |
FOERSTER F, HOPPE-LOTICHIUS M, VOLLMAR J, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre[J]. United European Gastroenterol J, 2019, 7(6): 838-849. DOI: 10.1177/2050640619840221 |
| [3] |
Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 |
| [4] |
AGOPIAN VG, HARLANDER-LOCKE M, ZARRINPAR A, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: Analysis of 865 consecutive liver transplant recipients[J]. J Am Coll Surg, 2015, 220(4): 416-427. DOI: 10.1016/j.jamcollsurg.2014.12.025 |
| [5] |
LAI Q, MELANDRO F, LARGHI LAUREIRO Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis[J]. World J Gastroenterol, 2018, 24(15): 1658-1665. DOI: 10.3748/wjg.v24.i15.1658 |
| [6] |
ORCI LA, BERNEY T, MAJNO PE, et al. Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Surg, 2015, 102(10): 1250-1257. DOI: 10.1002/bjs.9868 |
| [7] |
NAGAI S, YOSHIDA A, FACCIUTO M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation[J]. Hepatology, 2015, 61(3): 895-904. DOI: 10.1002/hep.27358 |
| [8] |
KHALAILEH A, KHOURY T, HARKROSH S, et al. Multiplication product of model for end-stage liver disease and donor risk index as predictive models of survival after liver transplantation[J]. Eur J Gastroenterol Hepatol, 2019, 31(9): 1116-1120. DOI: 10.1097/MEG.0000000000001396 |
| [9] |
LI MR, CHEN GH, CAI CJ, et al. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence[J]. Digestion, 2011, 84(2): 134-141. DOI: 10.1159/000324197 |
| [10] |
LAI Q, VITALE A, IESARI S, et al. The intention-to-treat effect of bridging treatments in the setting of Milan criteria-in patients waiting for liver transplantation[J]. Liver Transpl, 2019, 25(7): 1023-1033. DOI: 10.1002/lt.25492 |
| [11] |
MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4): 493-500. DOI: 10.1001/jamaoncol.2016.5116 |
| [12] |
MAZZAFERRO V, SPOSITO C, ZHOU J, et al. Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma[J]. Gastroenterology, 2018, 154(1): 128-139. DOI: 10.1053/j.gastro.2017.09.025 |
| [13] |
BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: Impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/SLA.0000000000001894 |
| [14] |
LEE DD, SAPISOCHIN G, MEHTA N, et al. Surveillance for HCC after liver transplantation: Increased monitoring may yield aggressive treatment options and improved post-recurrence survival[J]. Transplantation, 2020. [Epub ahead of print]
|
| [15] |
Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese criteria for diagnosis and treatment of primary recurrence after liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 278-280. (in Chinese)
中华医学会器官移植学分会. 中国肝移植术后随访技术规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 278-280.
|
| [16] |
LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26. DOI: 10.1002/lt.23566 |
| [17] |
FREISE CE, FERRELL L, LIU T, et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma[J]. Transplantation, 1999, 67(4): 510-513. DOI: 10.1097/00007890-199902270-00003 |
| [18] |
VIVARELLI M, CUCCHETTI A, PISCAGLIA F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression[J]. Liver Transpl, 2005, 11(5): 497-503. DOI: 10.1002/lt.20391 |
| [19] |
RODRÍGUEZ-PERÁLVAREZ M, TSOCHATZIS E, NAVEAS MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]. J Hepatol, 2013, 59(6): 1193-1199. DOI: 10.1016/j.jhep.2013.07.012 |
| [20] |
Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese code for immunosuppressive therapy and rejection in liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 262-268. (in Chinese)
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 262-268.
|
| [21] |
CHOLONGITAS E, MAMOU C, RODRÍGUEZ-CASTRO KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: A systematic review[J]. Transpl Int, 2014, 27(10): 1039-1049. DOI: 10.1111/tri.12372 |
| [22] |
THORAT A, JENG LB, YANG HR, et al. Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: Re-inventing the role of mammalian target of rapamycin inhibitors[J]. Ann Hepatobiliary Pancreat Surg, 2017, 21(4): 205-211. DOI: 10.14701/ahbps.2017.21.4.205 |
| [23] |
ZHANG ZH, LI LX, LI P, et al. Sirolimus in liver transplant recipients with hepatocellular carcinoma: An updated meta-analysis[J]. J Invest Surg, 2019, 32(7): 632-641. DOI: 10.1080/08941939.2018.1447053 |
| [24] |
GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10): 1260-1273. DOI: 10.1111/apt.15253 |
| [25] |
GEISSLER EK, SCHNITZBAUER AA, ZVLKE C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial[J]. Transplantation, 2016, 100(1): 116-125. DOI: 10.1097/TP.0000000000000965 |
| [26] |
Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese criteria for diagnosis and treatment of primary recurrence after liver transplantation (2019 Edition)[J/CD]. Chin J Transplant (Electronic Edition), 2019, 13(4): 273-277. (in Chinese)
中华医学会器官移植学分会. 中国肝移植术后原发病复发诊疗规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(4): 273-277.
|
| [27] |
Committee of Liver Transplantation, Chinese College of Transplant Doctors, Chinese Medical Doctor Association; Section of Liver Transplantation, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese expert consensus on application of sirolimus in liver transplantation for hepatocellular carcinoma (2020 edition)[J]. J Clin Hepatol, 2020, 36(11): 2429-2434. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.11.007 |
| [28] |
DUAN BW, TIAN LT, LIN DD, et al. Long-term consequences of stopping HBIG and/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection[J]. J Viral Hepat, 2019, 26(Suppl 1): 85-89.
|
| [29] |
SÖDERDAHL G, BÄCKMAN L, ISONIEMI H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma[J]. Transpl Int, 2006, 19(4): 288-294. DOI: 10.1111/j.1432-2277.2006.00279.x |
| [30] |
BERNAL E, MONTERO JL, DELGADO M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation[J]. Transplant Proc, 2006, 38(8): 2495-2498. DOI: 10.1016/j.transproceed.2006.08.053 |
| [31] |
SATAPATHY SK, DAS K, KOCAK M, et al. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant[J]. Clin Transplant, 2018, 32(5): e13246. DOI: 10.1111/ctr.13246 |
| [32] |
SHETTY K, DASH C, LAURIN J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma[J]. J Transplant, 2014, 2014: 913634.
|
| [33] |
BERENGUER M, BURRA P, GHOBRIAL M, et al. Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6): 1143-1149. DOI: 10.1097/TP.0000000000003196 |
| [34] |
SAPISOCHIN G, GOLDARACENA N, ASTETE S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series[J]. Ann Surg Oncol, 2015, 22(7): 2286-2294. DOI: 10.1245/s10434-014-4273-6 |
| [35] |
FERNANDEZ-SEVILLA E, ALLARD MA, SELTEN J, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?[J]. Liver Transpl, 2017, 23(4): 440-447. DOI: 10.1002/lt.24742 |
| [36] |
KORNBERG A, KVPPER B, TANNAPFEL A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: Clinical patterns and outcome variables[J]. Eur J Surg Oncol, 2010, 36(3): 275-280. DOI: 10.1016/j.ejso.2009.10.001 |
| [37] |
YANG Z, WANG S, TIAN XY, et al. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(4): 365-370. DOI: 10.1016/j.hbpd.2020.06.002 |
| [38] |
AU KP, CHOK K. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm[J]. World J Gastroenterol, 2018, 24(45): 5081-5094. DOI: 10.3748/wjg.v24.i45.5081 |
| [39] |
INVERNIZZI F, IAVARONE M, CZAUDERNA C, et al. Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: A real-life multicentre study[J]. Digest Liver Dis, 2019, 51(Suppl 1): e12.
|
| [40] |
LI H, YANG Z, LI R, et al. Regorafenib combined with sirolimus achieves successful treatment of diffuse double lung metastasis after liver transplantation in giant liver cancer beyond transplantation criteria: A case report[J]. Transplant Proc, 2020, 52(2): 634-637. DOI: 10.1016/j.transproceed.2019.12.001 |
| [41] |
ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1): 106. DOI: 10.1186/s40425-019-0585-1 |
| [42] |
KUMAR V, SHINAGARE AB, RENNKE HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature[J]. Oncologist, 2020, 25(6): 505-514. DOI: 10.1634/theoncologist.2019-0659 |
| [43] |
de BRUYN P, van GESTEL D, OST P, et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: How far can we go?[J]. Curr Opin Oncol, 2019, 31(2): 54-64. DOI: 10.1097/CCO.0000000000000505 |
| [44] |
AGUIRRE LE, GUZMAN ME, LOPES G, et al. Immune checkpoint inhibitors and the risk of allograft rejection: A comprehensive analysis on an emerging issue[J]. Oncologist, 2019, 24(3): 394-401. DOI: 10.1634/theoncologist.2018-0195 |
| [45] |
DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05 |
DownLoad: